依那西普治疗幼年特发性关节炎:无活动性疾病与缓解的预测因素
基于CLIPPER/CLIPPER2研究,分析依那西普治疗的幼年特发性关节炎患者中临床无活动性疾病(CID)和临床缓解(CR)的预测因素。约三分之二患者达到CID,34-43%达到CR;早期治疗反应(3个月JADAS低疾病活动度)、较小发病年龄、HLA-B27阳性及基线低疾病活动度与CID和CR相关。
要点
- 3个月时JADAS低疾病活动度是CID和CR的预测因素。
- 发病年龄≤12岁、HLA-B27阳性与JADAS定义的CID相关。
- 身高Z评分≥0.74和正常CRP水平预测JADAS CID。
核心结论
- 依那西普治疗的JIA患者中,早期治疗反应、较小年龄、HLA-B27阳性及基线低疾病活动度与CID和CR相关。
研究设计与样本
- 基于3b期开放标签CLIPPER研究(NCT00962741)及其8年延伸研究CLIPPER2(NCT01421069),纳入扩展型少关节炎(2-17岁)、附着点炎相关关节炎或银屑病关节炎(各12-17岁)患者,采用多变量逐步逻辑回归模型识别预测因素。
主要发现
- 约三分之二患者在任一时刻达到CID标准,34-43%达到CR。
- 身高Z评分≥0.74、发病年龄≤12岁、正常CRP水平、HLA-B27阳性、3个月时JADAS低疾病活动度及≤4个肿胀关节预测JADAS CID。
- BMI Z评分>0.80、发病年龄≤12岁、正常CRP水平及3个月时JADAS低疾病活动度预测JIA-ACR CID。
- 3个月时JADAS低疾病活动度预测JADAS CR;身高Z评分>1.23、3个月时JADAS低疾病活动度及>12个肿胀关节预测JIA-ACR CR。
关键数值与推荐
- CID根据幼年关节炎疾病活动评分(JADAS)和JIA-ACR反应标准定义;CR定义为CID持续≥6个月。
临床怎么用
- 对依那西普治疗的JIA患者,应关注3个月时的JADAS低疾病活动度以实现达标治疗,并考虑发病年龄、HLA-B27状态及基线疾病活动度。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify predictors of clinically inactive disease (CID) and clinical remission (CR) in patients with juvenile idiopathic arthritis receiving etanercept during the 2-year, phase 3b, open-label CLIPPER study (NCT00962741) and the 8-year extension study, CLIPPER2 (NCT01421069). METHODS: Patients with extended oligoarthritis (2-17 years), enthesitis-related arthritis or psoriatic arthritis (each 12-17 years) were enrolled in CLIPPER/CLIPPER2. Predictors of CID (according to Juvenile Arthritis Disease Activity Score [JADAS] and JIA-ACR response criteria) and CR (≥6 months of CID) were identified using a multivariate stepwise logistic regression model. RESULTS: Two-thirds of patients met the criteria for CID at any point and 34-43% achieved CR. Height Z-score ≥0.74, age at onset ≤12 years, normal CRP levels, HLA-B27+ status, JADAS low disease activity (LDA) at 3 months and ≤4 swollen joints were predictive of JADAS CID. BMI Z-score >0.80, age at onset ≤12 years, normal CRP levels and JADAS LDA at 3 months were predictors of JIA-ACR CID. JADAS LDA at 3 months was a predictor of JADAS CR, and height Z-score >1.23, JADAS LDA at 3 months and >12 swollen joints were identified as predictors of JIA-ACR CR. CONCLUSION: In patients with JIA treated with etanercept, early responses to treatment in line with treat-to-target recommendations, younger age, HLA-B27+ status and lower disease activity at baseline were associated with clinically inactive disease and clinical remission. TRIAL REGISTRATION: ClinicalTrials.gov IDs: CLIPPER (NCT00962741); CLIPPER2 (NCT01421069).
引用
- Chasnyk V, Constantin T, Nikishina I, et al. Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept. Rheumatology (Oxford). 2026. PMID: 42011511. doi:10.1093/rheumatology/keag198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。